Guardant Health, Inc. (NASDAQ:GH) Given Consensus Recommendation of "Buy" by Analysts

Guardant Health, Inc. (NASDAQ:GH - Get Free Report) has been assigned an average recommendation of "Buy" from the sixteen analysts that are covering the company, MarketBeat Ratings reports. Sixteen analysts have rated the stock with a buy recommendation. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $42.63.

A number of analysts recently commented on the company. JPMorgan Chase & Co. increased their price target on Guardant Health from $48.00 to $50.00 and gave the company an "overweight" rating in a research report on Thursday, November 7th. Leerink Partners decreased their target price on Guardant Health from $60.00 to $50.00 and set an "outperform" rating for the company in a research report on Thursday, October 17th. The Goldman Sachs Group raised their target price on Guardant Health from $36.00 to $49.00 and gave the stock a "buy" rating in a research report on Tuesday, January 28th. Sanford C. Bernstein decreased their target price on Guardant Health from $40.00 to $35.00 and set an "outperform" rating for the company in a research report on Wednesday, October 30th. Finally, Guggenheim reissued a "buy" rating on shares of Guardant Health in a research report on Wednesday, January 22nd.

Insider Activity at Guardant Health

In other Guardant Health news, Director Meghan V. Joyce sold 2,896 shares of Guardant Health stock in a transaction dated Wednesday, November 13th. The stock was sold at an average price of $29.90, for a total transaction of $86,590.40. Following the completion of the sale, the director now owns 7,648 shares of the company's stock, valued at $228,675.20. The trade was a 27.47 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Musa Tariq sold 2,320 shares of Guardant Health stock in a transaction dated Friday, December 13th. The stock was sold at an average price of $35.00, for a total value of $81,200.00. Following the sale, the director now directly owns 2,676 shares of the company's stock, valued at approximately $93,660. This trade represents a 46.44 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 5,548 shares of company stock valued at $179,782. Company insiders own 5.50% of the company's stock.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of GH. JNBA Financial Advisors purchased a new position in shares of Guardant Health in the third quarter worth about $26,000. R Squared Ltd purchased a new position in shares of Guardant Health in the fourth quarter worth about $26,000. Ashton Thomas Securities LLC purchased a new position in shares of Guardant Health in the third quarter worth about $34,000. SBI Securities Co. Ltd. purchased a new position in shares of Guardant Health in the fourth quarter worth about $43,000. Finally, Nisa Investment Advisors LLC increased its holdings in Guardant Health by 168.1% during the 3rd quarter. Nisa Investment Advisors LLC now owns 3,434 shares of the company's stock valued at $79,000 after purchasing an additional 2,153 shares during the period. Hedge funds and other institutional investors own 92.60% of the company's stock.

Guardant Health Stock Performance

NASDAQ:GH traded down $1.62 on Tuesday, hitting $44.47. The stock had a trading volume of 6,162,854 shares, compared to its average volume of 2,547,098. The stock has a market cap of $5.49 billion, a P/E ratio of -10.49 and a beta of 1.32. The firm's fifty day simple moving average is $37.94 and its two-hundred day simple moving average is $30.59. Guardant Health has a 1 year low of $15.81 and a 1 year high of $50.89.

Guardant Health (NASDAQ:GH - Get Free Report) last issued its quarterly earnings results on Wednesday, November 6th. The company reported ($0.88) EPS for the quarter, missing analysts' consensus estimates of ($0.55) by ($0.33). The business had revenue of $191.48 million for the quarter, compared to analysts' expectations of $170.49 million. Guardant Health had a negative net margin of 74.02% and a negative return on equity of 1,200.44%. The business's revenue was up 33.9% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.73) earnings per share. Equities research analysts predict that Guardant Health will post -3.43 EPS for the current year.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.